Bisphosphonate nephrotoxicity (Q37237318)

19 August 2017

1 reference

title

Bisphosphonate nephrotoxicity (English)

1 reference

19 August 2017

Mark A Perazella

1

1 reference

PubMed ID

18685574

19 August 2017

Glen S Markowitz

series ordinal

2

1 reference

PubMed ID

18685574

19 August 2017

language of work or name

English

0 references

publication date

6 August 2008

1 reference

19 August 2017

1 reference

19 August 2017

74

1 reference

19 August 2017

1385-1393

1 reference

19 August 2017

11

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.2008.356

19 August 2017

0 references

cites work

Safety of intravenous and oral bisphosphonates and compliance with dosing regimens

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Bisphosphonates: from the laboratory to the clinic and back again

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Renal safety of ibandronate

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Integrin-mediated signals regulated by members of the rho family of GTPases

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

The small GTP-binding protein rac regulates growth factor-induced membrane ruffling

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Etidronate (EHDP) inhibits osteoclastic-bone resorption, promotes apoptosis and disrupts actin rings in isolate-mature osteoclasts.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Bisphosphonates: a review of their pharmacokinetic properties

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Ibandronate: a clinical pharmacological and pharmacokinetic update

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Preclinical perspectives on bisphosphonate renal safety

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Transmission of human herpesvirus 8 by blood transfusion

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Zoledronic acid and clinical fractures and mortality after hip fracture

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Disposition and nephrotoxicity of 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD), in rats and mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Urinary gamma-glutamyl transferase in renal toxicology of the rat. Bases of its use and significance in acute mercurial nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Acute renal effects of intravenous bisphosphonates in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Podocyte injury associated glomerulopathies induced by pamidronate

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Nephrotic syndrome after treatment with pamidronate

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Collapsing glomerulopathy induced by long-term treatment with standard-dose pamidronate in a myeloma patient

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Multiple myeloma, nephrotic syndrome and crystalloid inclusions in podocytes.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Pamidronate-induced nephrotoxic tubular necrosis--a case report.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Pamidronate-induced tubulointerstitial nephritis with Fanconi syndrome in a patient with primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Toxic acute tubular necrosis following treatment with zoledronate (Zometa).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Renal Failure with the Use of Zoledronic Acid

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Zoledronic Acid and renal toxicity: data from French adverse effect reporting database

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Ibandronate in the treatment of prostate cancer associated painful osseous metastases

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Cellular focal segmental glomerulosclerosis: Clinical and pathologic features

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.356

7 January 2021

Identifiers

DOI

10.1038/KI.2008.356

1 reference

19 August 2017

1 reference

PubMed ID

18685574